US Stock MarketDetailed Quotes

BCAX Bicara Therapeutics

Watchlist
  • 20.790
  • -0.170-0.81%
Close Nov 29 13:00 ET
  • 20.790
  • 0.0000.00%
Post 13:00 ET
1.13BMarket Cap-19021P/E (TTM)

Bicara Therapeutics Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Quarterly+Annual
YOY yoy
Hide blank lines yoy
(Q3)Sep 30, 2024
(FY)Dec 31, 2023
(Q4)Dec 31, 2023
(Q3)Sep 30, 2023
(FY)Dec 31, 2022
Total revenue
0
0
0
0
0
Operating revenue
--0
--0
--0
--0
--0
Cost of revenue
Gross profit
Operating expense
116.45%20.63M
5.93%39.89M
13.69M
9.53M
37.66M
Selling and administrative expenses
83.87%4.76M
46.15%9.27M
--3.13M
--2.59M
--6.34M
-General and administrative expense
83.87%4.76M
46.15%9.27M
--3.13M
--2.59M
--6.34M
Research and development costs
128.62%15.86M
-2.22%30.62M
--10.56M
--6.94M
--31.31M
Operating profit
-116.45%-20.63M
-5.93%-39.89M
-13.69M
-9.53M
-37.66M
Net non-operating interest income expense
24,107.69%3.15M
1,316.67%1.31M
1.3M
13K
-108K
Non-operating interest income
24,107.69%3.15M
32,750.00%1.31M
--1.3M
--13K
--4K
Non-operating interest expense
----
--0
----
----
--112K
Other net income (expense)
-16,656.25%-13.41M
-49K
-13.33M
-80K
Other non- operating income (expenses)
----
-16,656.25%-13.41M
---49K
---13.33M
---80K
Income before tax
23.48%-17.48M
-37.35%-51.98M
-12.44M
-22.85M
-37.84M
Income tax
0
400.00%5K
5K
0
1K
Net income
23.48%-17.48M
-37.36%-51.99M
-12.44M
-22.85M
-37.85M
Net income continuous Operations
23.48%-17.48M
-37.36%-51.99M
---12.44M
---22.85M
---37.85M
Minority interest income
Net income attributable to the parent company
23.48%-17.48M
-37.36%-51.99M
-12.44M
-22.85M
-37.85M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders
23.48%-17.48M
-37.36%-51.99M
-12.44M
-22.85M
-37.85M
Basic earnings per share
-138.02%-1.6
-37.49%-3.37
-0.366
-0.6722
-2.451
Diluted earnings per share
-138.02%-1.6
-37.49%-3.37
-0.366
-0.6722
-2.451
Dividend per share
Currency Unit
USD
USD
USD
USD
USD
(Q3)Sep 30, 2024(FY)Dec 31, 2023(Q4)Dec 31, 2023(Q3)Sep 30, 2023(FY)Dec 31, 2022
Total revenue 00000
Operating revenue --0--0--0--0--0
Cost of revenue
Gross profit
Operating expense 116.45%20.63M5.93%39.89M13.69M9.53M37.66M
Selling and administrative expenses 83.87%4.76M46.15%9.27M--3.13M--2.59M--6.34M
-General and administrative expense 83.87%4.76M46.15%9.27M--3.13M--2.59M--6.34M
Research and development costs 128.62%15.86M-2.22%30.62M--10.56M--6.94M--31.31M
Operating profit -116.45%-20.63M-5.93%-39.89M-13.69M-9.53M-37.66M
Net non-operating interest income expense 24,107.69%3.15M1,316.67%1.31M1.3M13K-108K
Non-operating interest income 24,107.69%3.15M32,750.00%1.31M--1.3M--13K--4K
Non-operating interest expense ------0----------112K
Other net income (expense) -16,656.25%-13.41M-49K-13.33M-80K
Other non- operating income (expenses) -----16,656.25%-13.41M---49K---13.33M---80K
Income before tax 23.48%-17.48M-37.35%-51.98M-12.44M-22.85M-37.84M
Income tax 0400.00%5K5K01K
Net income 23.48%-17.48M-37.36%-51.99M-12.44M-22.85M-37.85M
Net income continuous Operations 23.48%-17.48M-37.36%-51.99M---12.44M---22.85M---37.85M
Minority interest income
Net income attributable to the parent company 23.48%-17.48M-37.36%-51.99M-12.44M-22.85M-37.85M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders 23.48%-17.48M-37.36%-51.99M-12.44M-22.85M-37.85M
Basic earnings per share -138.02%-1.6-37.49%-3.37-0.366-0.6722-2.451
Diluted earnings per share -138.02%-1.6-37.49%-3.37-0.366-0.6722-2.451
Dividend per share
Currency Unit USDUSDUSDUSDUSD

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
US
Overall
Symbol
Latest Price
% Chg

No Data

Investment Theme Recent IPOs
Recent IPOs
Intraday+0.64%